Hypera S.A. Hypera S.A.

Hypera S.A.

HYPE3

Rang in Aktien #4245
Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical... Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical enterprise. The company's comprehensive product line encompasses a wide array of prescription medications, featuring established brands such as Adacne, Celestamine, Cizax, Diprosone, and Emprol XR, among many others. Beyond prescription drugs, Hypera offers specialized dermo-cosmetics through its Mantecorp Skincare brand. Its consumer health division markets popular remedies like Apracur, Benegrip, Engov, and Estomazil. Additionally, Hypera provides nutritional and vitamin supplements, including well-known names such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. The company also maintains a significant presence in the generic and similar medicines market, offering products under the Neo Química brand and common formulations like Ibuprofen, Paracetamol, and Omeprazole. The organization officially became Hypera S.A. in February 2018, having previously operated as Hypermarcas S.A.
Aktienkurs
$5.31
Marktkapitalisierung
$3.74B
Veränderung (1 Tag)
1.78%
Veränderung (1 Jahr)
24.80%
Land
BR
Handel Hypera S.A. (HYPE3)

Kategorie

Healthcare
Dividendenrendite-Verlauf für Hypera S.A. (HYPE3)
Dividendenrendite (TTM) von Hypera S.A. (Aktienkürzel: HYPE3) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Hypera S.A. (HYPE3) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber